Antirheumatic Therapy: Actions and Outcomes (Record no. 245812)

MARC details
000 -LEADER
fixed length control field 03783nam a22004935i 4500
001 - CONTROL NUMBER
control field 978-3-7643-7726-7
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20160614135157.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100529s2005 sz | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783764377267
-- 978-3-7643-7726-7
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-3-7643-7726-7
Source of number or code doi
049 ## - LOCAL HOLDINGS (OCLC)
Holding library Alfaisal Main Library
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number R1
072 #7 - SUBJECT CATEGORY CODE
Subject category code MB
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED000000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 610
Edition number 23
245 10 - TITLE STATEMENT
Title Antirheumatic Therapy: Actions and Outcomes
Medium [electronic resource] /
Statement of responsibility, etc edited by Richard O. Day, Daniel E. Fürst, Piet L. C. M. van Riel, Barry Bresnihan.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE STATEMENTS
Place of production, publication, distribution, manufacture Basel :
Name of producer, publisher, distributor, manufacturer Birkhäuser Basel,
Date of production, publication, distribution, manufacture 2005.
300 ## - PHYSICAL DESCRIPTION
Extent XIII, 343 p.
Other physical details online resource.
336 ## - CONTENT TYPE
Content Type Term text
Content Type Code txt
Source rdacontent
337 ## - MEDIA TYPE
Media Type Term computer
Media Type Code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier Type Term online resource
Carrier Type Code cr
Source rdacarrier
347 ## -
-- text file
-- PDF
-- rda
490 1# - SERIES STATEMENT
Series statement Progress in Inflammation Research
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Medicinal chemistry of the disease modifying anti-rheumatic drugs -- Targeting DMARD therapy -- Pharmacoeconomic properties of disease-modifying antirheumatic drugs -- Future molecular targets -- Hydroxychloroquine -- Sulfasalazine -- Parenteral gold -- Azathioprine -- Methotrexate -- Leflunomide -- Cyclosporin -- Tetracyclines -- Systemic glucocorticoids in rheumatoid arthritis -- TNF-? inhibitors -- Anakinra in rheumatoid arthritis -- Combination therapy -- Hematopoietic stem cell transplantation for the treatment of severe autoimmune diseases.
520 ## - SUMMARY, ETC.
Summary, etc Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short­ term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor­ der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi­ cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long­ term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav­ elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine & Public Health.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine/Public Health, general.
655 #7 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
Source of term local
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Day, Richard O.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Fürst, Daniel E.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Riel, Piet L. C. M. van.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Bresnihan, Barry.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9783764365950
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Progress in Inflammation Research
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1007/978-3-7643-7726-7">http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1007/978-3-7643-7726-7</a>
912 ## -
-- ZDB-2-SME
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Library of Congress Classification
Koha item type eBooks

No items available.

Copyright © 2020 Alfaisal University Library. All Rights Reserved.
Tel: +966 11 2158948 Fax: +966 11 2157910 Email:
librarian@alfaisal.edu